BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Alzheimer’s disease (AD) is a growing global health concern with a massive impact on affected individuals and society. Despite the considerable advances achieved in the understanding of AD pathogenesis, researchers have not been successful in fully identifying the mechanisms involved in di...
Main Authors: | Miguel A. Maia, Emília Sousa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-03-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/12/1/41 |
Similar Items
-
BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
by: Gerald Koelsch
Published: (2017-10-01) -
Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1
by: Courtney J. Mycroft-West, et al.
Published: (2021-04-01) -
Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics
by: Shiveena Bhatia, et al.
Published: (2023-08-01) -
Role of BACE1 in Alzheimer’s synaptic function
by: Brati Das, et al.
Published: (2017-08-01) -
A Glycosaminoglycan Extract from <i>Portunus pelagicus</i> Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease
by: Courtney J. Mycroft-West, et al.
Published: (2019-05-01)